An Early Phase 1 interventional study of Latanoprost and Minoxidil in Hypotrichosis, sponsored by Aneira Pharma, Inc.. Status unknown at 1 site in United States. Open to participants aged 22 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-30.
Sponsored by Aneira Pharma, Inc. · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Hypotrichosis with a site in United States — 2 open to participants now, 3 under way, 1 of them phase 3. Hypotrichosis · United States.
Among the 15 studies in Hypotrichosis with a site in United States, this one is the 13th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is the only one in phase 1, and was the 14th registered.
24 studies on the registry are indexed under Hypotrichosis; 2 are open to participants now.
Browse Hypotrichosis studies →2 of the 15 studies in Hypotrichosis with a site in United States are open now. Recruiting first, the newest first:
Almirall, S.A. · Sites in United States
Ages 18–65
Eli Lilly and Company · Sites in United States, Argentina, Australia and 9 more countries
Ages 6–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 2 Hypotrichosis studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 22 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 56 across 22 interventional studies indexed under Hypotrichosis.
Median enrollment 89 across the 14 interventional studies, 585 across the 1 observational. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 15 have an industry lead sponsor. The 9 most frequent:
Aneira Pharma, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Aneira Pharma, Inc. has 1 study filed under Hypotrichosis — fewer than ten, so there is no comparison to draw.
2 of the studies in Hypotrichosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04018859Northwestern UniversityPlatelet-rich Plasma for Eyebrows | 2027-05 |
| NCT07311564Almirall, S.A.A Study of LAD603 in Adults With Alopecia Areata | 2027-06-23 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Hypotrichosis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study to Evaluate the safety and efficacy of a Latanoprost/Minoxidil formulation vs. placebo for the treatment of hypotrichosis of the eyebrows.
A Single-Blind placebo controlled trial of the efficacy and safety of the treatment of hypotrichosis of the eyebrows comparing a subset of patients receiving a combination of latanoprost/minoxidil formulation as compared to placebo measured by a validated imaging system.
Inclusion Criteria: • Subjects, age 22 to 65 years, in general good health.
Exclusion Criteria: • Subjects with an active disease or infection, or chronic dermatological condition (eczema, psoriasis, infection, etc.) of the scalp that may interfere with the assessment of scalp skin health in the treated regions.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
8 participants: Topical Latanoprost/Minoxidil formulation applied to both eyebrows once a day for 90 days
Combination Product: Latanoprost and Minoxidil
4 participants: Vehicle applied to both eyebrows once a day for 90 days
Combination Product: Latanoprost and Minoxidil
Drug pages: Latanoprost · Minoxidil
Latanoprost and Minoxidil formulation for the treatment of hypotrichosis of the eyebrows.
Target Area Hair Count
Target Area Hair Count as Determined by the Brigham Tool for Alopecia
Time frame: 90 days
Standardized Global Photographs
1. Standardized Global Photographs and change from baseline measurement of eyebrow hair fullness using Canfield Eyebrow Hair Image Analysis.
Time frame: 90 days
Change in Total Area Hair Darkness
2. Change in Total Area Hair Darkness of non-vellus hairs as compared to baseline in target area, defined as change from baseline of non-vellus hairs measured in intensity units as determined by Canfield Eyebrow Hair Image Analysis.
Time frame: 90 days
Subject Self Assessment
1. Subject Self-Assessment and Investigator Global Assessment using a Canfield side-by-side comparison tool on Day 90. Measure participant's satisfaction with eyebrow treatment.
Time frame: 90 Days
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Jun 2023, 3 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Latanoprost · Minoxidil
Aneira Pharma, Inc.